BioLife Solutions, Inc. (NASDAQ:BLFS) Given Consensus Rating of “Buy” by Analysts

Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) have received a consensus recommendation of “Buy” from the six analysts that are covering the stock, Marketbeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $27.50.

A number of analysts have recently weighed in on BLFS shares. TD Cowen increased their price objective on BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Craig Hallum increased their price target on shares of BioLife Solutions from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. HC Wainwright decreased their price objective on shares of BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a research report on Monday, November 18th. Finally, Northland Securities upped their price objective on shares of BioLife Solutions from $26.00 to $28.00 and gave the company an “outperform” rating in a research note on Friday, August 9th.

Insider Transactions at BioLife Solutions

In related news, EVP Aby J. Mathew sold 17,604 shares of the company’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $20.05, for a total value of $352,960.20. Following the sale, the executive vice president now directly owns 284,442 shares of the company’s stock, valued at $5,703,062.10. This represents a 5.83 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CRO Garrie Richardson sold 3,070 shares of the firm’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $25.12, for a total value of $77,118.40. Following the transaction, the executive now directly owns 114,773 shares of the company’s stock, valued at $2,883,097.76. This represents a 2.61 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 69,644 shares of company stock valued at $1,527,503. Company insiders own 2.20% of the company’s stock.

Hedge Funds Weigh In On BioLife Solutions

A number of institutional investors and hedge funds have recently modified their holdings of the company. Mark Sheptoff Financial Planning LLC bought a new position in shares of BioLife Solutions in the third quarter worth approximately $28,000. 1620 Investment Advisors Inc. purchased a new position in BioLife Solutions during the 2nd quarter valued at $35,000. Isthmus Partners LLC grew its holdings in shares of BioLife Solutions by 34.4% in the second quarter. Isthmus Partners LLC now owns 165,247 shares of the medical equipment provider’s stock worth $35,000 after purchasing an additional 42,265 shares during the last quarter. Quest Partners LLC bought a new position in BioLife Solutions in the 3rd quarter worth about $57,000. Finally, GAMMA Investing LLC grew its stake in BioLife Solutions by 29.4% in the third quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock worth $83,000 after purchasing an additional 748 shares in the last quarter. 93.24% of the stock is currently owned by hedge funds and other institutional investors.

BioLife Solutions Stock Performance

BioLife Solutions stock opened at $27.16 on Friday. The firm has a fifty day simple moving average of $24.16 and a two-hundred day simple moving average of $23.16. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03. BioLife Solutions has a twelve month low of $11.91 and a twelve month high of $28.88. The company has a market capitalization of $1.26 billion, a PE ratio of -25.62 and a beta of 1.88.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.